Exelixis, Inc. (NASDAQ: EXEL) today announced that cabozantinib and cobimetinib will be the subject of ten presentations at the upcoming 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting, which will be held May 30 to June 3, 2014 in Chicago, Illinois, is expected to draw more than 25,000 oncology professionals from around the world.
The full roster of cabozantinib presentations expected at the meeting (all times Central Daylight Time):
Poster Discussion Presentation
- Abstract 4501: “Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.”[Note: This is an NCI-CTEP study.]Dr. Andrea Apolo, Center for Cancer Research, National Cancer Institute, Bethesda, MDOral Abstract Session: Genitourinary CancerMonday, June 2, 9:45 a.m. - 12:45 p.m., E Hall D1 (talk from 9:57-10:09 a.m.)
- Abstract 5027/Poster 42: “ Phase 1 dose finding study of cabozantinib (cabo) + abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study.”[Note: This is an Investigator-Sponsored Trial.]Dr. Christopher Sweeney, The Dana Farber Cancer Institute, Boston, MAPoster Highlights Session: Genitourinary (Prostate) CancerSaturday, May 31, 1:15-4:15 p.m. (poster display, E354b); 4:45-6:00 p.m. (discussion, E354b)
General Poster Presentations
- Abstract 8014/Poster 28: “Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: a California Cancer Consortium phase II trial (NCI 9303).”[Note: This is an NCI-CTEP study.]Dr. Karen Reckamp, City of Hope Cancer Center, Duarte, CaliforniaPoster Highlights Session: Lung CancerTuesday, June 3, 8:00–11:00 a.m. (poster display, room E354b); 11:30 a.m.–12:45 p.m. (discussion, E354b)
- Abstract TPS4150/Poster 234A: “Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).”Dr. Ghassan K. Abou-Alfa, Memorial Sloan-Kettering Cancer Center, New YorkGeneral Poster Session: Gastrointestinal (Noncolorectal) CancerSaturday, May 31, 8:00-11:45 a.m., South Hall A2[Note: This is a Trials in Progress abstract.]
- Abstract TPS4157/Poster 237B: “A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors.”[Note: This is an Investigator-Sponsored Trial, and a Trials in Progress abstract.]Dr. Jason Faris, Massachusetts General Hospital, Boston, MAGeneral Poster Session: Gastrointestinal (Noncolorectal) CancerSaturday, May 31, 8:00-11:45 a.m., South Hall A2
- Abstract TPS5629/Poster 402A: “Phase II study of XL184 (Cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago and California Phase II Consortia.”[Note: This is an NCI-CTEP study, and a Trials in Progress abstract.]Dr. Michelle Wilson, Princess Margaret Cancer Centre, Toronto, Ontario, CanadaGeneral Poster Session: Gynecologic CancerSaturday, May 31, 8:00-11:45 a.m., South Hall A2
- Abstract 10078/Poster 379: “A phase I study of Cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children’s Oncology Group phase I consortium trial.”[Note: This is an NCI-CTEP study.]Dr. Meredith K. Chuk, The Johns Hopkins Hospital, Baltimore, MDGeneral Poster Session: Pediatric OncologyMonday, June 2, 8:00-11:45 a.m., South Hall A2
- Abstract TPS4601/Poster 163A: “Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with clear cell renal cell carcinoma (METEOR).”[Note: This is a Trials in Progress abstract.]Dr. Toni K. Choueiri, Dana Farber Cancer Institute, Boston, MAGeneral Poster Session: Genitourinary CancerMonday, June 2, 1:15-5:00 p.m ., South Hall A2
The cobimetinib oral presentation expected at the meeting (time Central Daylight Time):
- Abstract 5072/Poster 201: “A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).”[Note: This is an NCI-CTEP study.]Dr. Fatima Karzai, Center for Cancer Research, National Cancer Institute, Bethesda, MDGeneral Poster Session: Genitourinary CancerMonday, June 2, 1:15–5:00 p.m., South Hall A2
- Abstract 9006: “ Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.”Prof. Grant A. MacArthur, Peter MacCallum Cancer Centre, Victoria, AustraliaOral Abstract Session: Melanoma/Skin CancersMonday, June 2, 3:00-6:00 p.m, E Arie Crown Theater (talk from 4:36–4:48 p.m.)
Cabozantinib inhibits the activity of tyrosine kinases including MET, VEGFRs and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.